SAN FRANCISCO (AP) _ FibroGen Inc. (FGEN) on Monday reported a loss of $72.6 million in its second quarter.

The San Francisco-based company said it had a loss of 78 cents per share.

The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 94 cents per share.

The biotech drug developer posted revenue of $29.8 million in the period, falling short of Street forecasts. Four analysts surveyed by Zacks expected $36.6 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FGEN at https://www.zacks.com/ap/FGEN

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News